ReviewEuropean respiratory review : an official journal of the European Respiratory Society2018
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
Review in European respiratory review : an official journal of the European Respiratory Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05468346 (Clinical Trial of Absorption, Metabolism and Excretion of [14C]-HEC585 in Chinese Adult Male Healthy Subjects), which is not on this map. Cited by 107 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of Absorption, Metabolism and Excretion of [14C]-HEC585 in Chinese Adult Male Healthy Subjects
Who cites it
107 citing papers in PubMed, 4 syntheses or guidelines pooled it, 192 citations in OpenAlex.
- Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Lack of diversity in antifibrotic trials for pulmonary fibrosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies.Stem cell research & therapy · 2021Pooled it
- Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.Advances in therapy · 2021Pooled it
- Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus.Pneumologie (Stuttgart, Germany) · 2024Trial
- Club Cell Loss as a Feature of Bronchiolization in ILD.Frontiers in immunology · 2021Trial
- Doublecortin-like kinase 1 promotes fibroblast activation and fibrotic progression through Smad3 binding in idiopathic pulmonary fibrosis.Journal of biomedical science · 2026Article
- Mortality and diagnostic practice variation in interstitial lung disease admissions: insights from a multicentre UK cohort study.BMJ open respiratory research · 2026Article
- Triggering Receptor Expressed on Myeloid Cells-2 Regulates Innate Lymphoid Cell Levels in Bleomycin-Induced Pulmonary Fibrosis.The Kaohsiung journal of medical sciences · 2026Article
- Tweaking the Complex Fibrogenic Role of Lymphocytes in Idiopathic Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Article
- Characteristics of CLA⁺Tregs in rheumatoid arthritis and their potential as biomarkers of treatment response.Arthritis research & therapy · 2026Article
- Decoding the ubiquitination-immunity axis in idiopathic pulmonary fibrosis: diagnostic insights and therapeutic implications.Respiratory research · 2026Article
- National and provincial burden of interstitial lung disease mortality in China, 2013-2021: a nationwide analysis of trends and underlying cause of death.Respiratory research · 2026Article
- Microplastics as environmental modifiers of lung disease.EMBO molecular medicine · 2026Review
- Epidemiology of idiopathic pulmonary fibrosis: a population registry-based study.Orphanet journal of rare diseases · 2026Article
- Polystyrene-associated pulmonary fibrosis: a summary based on the available evidence and prospects.Frontiers in immunology · 2026Review
- Frailty and functional outcomes in patients with progressive fibrosing interstitial lung diseases receiving antifibrotic therapy: a real-life observational study.Frontiers in medicine · 2026Article
- Prognostic risk model based on cholesterol metabolism-Associated gene module for idiopathic pulmonary fibrosis.PloS one · 2026Article
- Article
- Improvement of Number 2 Feibi Recipe on pulmonary fibrosis in mice by inhibiting the level of miR-199a-5p and activating autophagy.Scientific reports · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of epidemiological data relating to interstitial lung diseases (ILDs) has increased over recent years, but information on the prevalence and incidence of ILDs of different aetiologies remains limited. Despite global distribution, the proportion of patients who develop a progressive phenotype across different ILDs is not well known. Disease behaviour is well documented in idiopathic pulmonary fibrosis but idiosyncratic in other ILDs that may present a progressive fibrosing phenotype. Possible reasons may include the heterogeneous nature of the aetiology, the complexity of diagnosis (and subsequent documentation of cases) and the methods employed to retrospectively analyse patient databases. This review presents a broad overview of the epidemiological data available for ILDs that may present a progressive-fibrosing phenotype, collectively and stratified according to clinical classification. We also note where further data are needed in comparison to the well-studied IPF indication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.